CO COHANCE
Cohance Lifesciences Q4 2026
COCOHANCE

Cohance Lifesciences Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 12 May 2026

Management summary

  • Cohance Lifesciences reported a challenging FY26 with a 13% YoY revenue decline to INR 2,268 crores and an EBITDA margin of 21%, primarily due to destocking and customer inventory adjustments.
  • Management expects Q1 FY27 to be weak, with recovery anticipated from H2 FY27.
  • Execution on existing programs and new commercial launches..
  • The company remains focused on strengthening its differentiated capabilities in ADCs and oligonucleotides and improving operational rigor.

Source: Inve concall analysis and management guidance record.

Highlights

  • Gross margin remained strong at 70.8% for FY26, supported by product mix, backward integration, and cost actions.

  • New business conversion with innovator pharma and biotech customers remains healthy.

  • The Phase 3 pipeline has expanded to 10 programs, with two molecules moving into commercialization.

  • API+ business saw sequential improvement in H2 FY26 with stabilized supply execution and strengthened customer engagement.

What they filed

Q4 FY26: revenue down 26.3%, net profit down 92.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue676 840 549 556 545 −19%619 −26%
EBITDA237 229 112 121 95 −60%99 −57%
Net profit153 117 46 66 29 −81%8 −93%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Capex

  • Capex Spend Capex · FY27 · High confidence INR 3 billion

Revenue Growth

  • Overall Growth Revenue Growth · FY27 · Medium confidence return from second half

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Contribution of large molecules and new commercial products to FY27 revenue Partial
Yes, so from a return, we are in active discussion with both the customers and we expect there would be a return in both these molecules. However, you will have to allow us to have meaningful conversations crystallize into orders before which we communicate to you on the actual a

Analysts sought specific quantification for revenue recovery from previously impacted products and new launches, but management provided only qualitative and directional timelines.

Asked by Karthi

Breakup of one-time expenses (INR109 crore) over last two years Direct
Yes. So I will tell you about this year. I think this year, on a one-time expenses, there are two large elements. One is that we have taken a one-off inventory provision, which is around 195 million. And we have also provided for certain customer adjustments, that is in the range

Management clarified the components of significant one-time expenses, providing transparency on non-recurring items impacting profitability.

Asked by Karthi

Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 10 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY27
  • +6 more guidance targets & verbatim management quotes
  • +5 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image